Literature DB >> 9736530

Pharmacokinetics and distribution over the blood-brain barrier of zalcitabine (2',3'-dideoxycytidine) and BEA005 (2', 3'-dideoxy-3'-hydroxymethylcytidine) in rats, studied by microdialysis.

N Borg1, L Ståhle.   

Abstract

Microdialysis was applied to sample the unbound drug concentration in the extracellular fluid in brain and muscle of rats given zalcitabine (2',3'-dideoxycytidine; n = 4) or BEA005 (2', 3'-dideoxy-3'-hydroxymethylcytidine; n = 4) (50 mg/kg of body weight given subcutaneously). Zalcitabine and BEA005 were analyzed by high-pressure liquid chromatography with UV detection. The maximum concentration of zalcitabine in the dialysate (Cmax) was 31.4 +/- 5. 1 microM (mean +/- standard error of the mean) for the brain and 238. 3 +/- 48.1 microM for muscle. The time to Cmax was found to be from 30 to 45 min for the brain and from 15 to 30 min for muscle. Zalcitabine was eliminated from the brain and muscle with half-lives 1.28 +/- 0.64 and 0.85 +/- 0.13 h, respectively. The ratio of the area under the concentration-time curve (AUC) (from 0 to 180 min) for the brain and the AUC for muscle (AUC ratio) was 0.191 +/- 0.037. The concentrations of BEA005 attained in the brain and muscle were lower than those of zalcitabine, with Cmaxs of 5.7 +/- 1.4 microM in the brain and 61.3 +/- 12.0 microM in the muscle. The peak concentration in the brain was attained 50 to 70 min after injection, and that in muscle was achieved 30 to 50 min after injection. The half-lives of BEA005 in the brain and muscle were 5.51 +/- 1.45 and 0.64 +/- 0.06 h, respectively. The AUC ratio (from 0 to 180 min) between brain and muscle was 0.162 +/- 0.026. The log octanol/water partition coefficients were found to be -1.19 +/- 0.04 and -1.47 +/- 0.01 for zalcitabine and BEA005, respectively. The degrees of plasma protein binding of zalcitabine (11% +/- 4%) and BEA005 (18% +/- 2%) were measured by microdialysis in vitro. The differences between zalcitabine and BEA005 with respect to the AUC ratio (P = 0.481), half-life in muscle (P = 0.279), and level of protein binding (P = 0.174) were not statistically significant. The differences were statistically significant in the case of the half-life in the brain (P = 0.032), clearance (P = 0.046), volume of distribution (P = 0.027) in muscle, and octanol/water partition coefficient (P = 0.019).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9736530      PMCID: PMC105766     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  A comparison between three methods for estimation of extracellular concentrations of exogenous and endogenous compounds by microdialysis.

Authors:  L Ståhle; S Segersvärd; U Ungerstedt
Journal:  J Pharmacol Methods       Date:  1991-03

2.  Pyrimidine dideoxyribonucleosides: selectivity of penetration into cerebrospinal fluid.

Authors:  J M Collins; R W Klecker; J A Kelley; J S Roth; C L McCully; F M Balis; D G Poplack
Journal:  J Pharmacol Exp Ther       Date:  1988-05       Impact factor: 4.030

3.  Microdialysis sampling for determination of plasma protein binding of drugs.

Authors:  A M Herrera; D O Scott; C E Lunte
Journal:  Pharm Res       Date:  1990-10       Impact factor: 4.200

4.  High-performance liquid chromatographic method for the analysis of 2',3'-dideoxycytidine in human plasma.

Authors:  M E Hawkins; D G Poplack; P A Pizzo; F M Balis
Journal:  J Chromatogr       Date:  1990-11-16

5.  Use of multivariate characterization, design and analysis in assay optimization.

Authors:  L Ståhle; A Mian; N Borg
Journal:  J Pharm Biomed Anal       Date:  1995-04       Impact factor: 3.935

6.  Theophylline concentration in the extracellular space of the rat brain: measurement by microdialysis and relation to behaviour.

Authors:  L Ståhle; S Segersvärd; U Ungerstedt
Journal:  Eur J Pharmacol       Date:  1990-08-28       Impact factor: 4.432

Review 7.  Pharmacodynamics of 2',3'-dideoxycytidine: an inhibitor of human immunodeficiency virus.

Authors:  S Broder
Journal:  Am J Med       Date:  1990-05-21       Impact factor: 4.965

8.  Pharmacokinetics of 2',3'-dideoxycytidine after high-dose administration to rats.

Authors:  S S Ibrahim; F D Boudinot
Journal:  J Pharm Sci       Date:  1991-01       Impact factor: 3.534

9.  Drug distribution studies with microdialysis. II. Caffeine and theophylline in blood, brain and other tissues in rats.

Authors:  L Ståhle; S Segersvärd; U Ungerstedt
Journal:  Life Sci       Date:  1991       Impact factor: 5.037

10.  Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders.

Authors:  R W Klecker; J M Collins; R C Yarchoan; R Thomas; N McAtee; S Broder; C E Myers
Journal:  J Clin Pharmacol       Date:  1988-09       Impact factor: 3.126

View more
  5 in total

1.  GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats.

Authors:  Jeffrey E Edwards; Kenneth R Brouwer; Patrick J McNamara
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

Review 2.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.

Authors:  Markus Müller; Amparo dela Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

3.  2',3'-Dideoxycytidine Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease.

Authors:  Jianyi Niu; Jing Xiong; Dan Hu; Fei Zeng; Shuke Nie; Shanping Mao; Tao Wang; Zhentao Zhang; Zhaohui Zhang
Journal:  Neurochem Res       Date:  2017-06-19       Impact factor: 3.996

4.  A recursive-partitioning model for blood-brain barrier permeation.

Authors:  S R Mente; F Lombardo
Journal:  J Comput Aided Mol Des       Date:  2005-12-06       Impact factor: 3.686

Review 5.  Antiretroviral bioanalysis methods of tissues and body biofluids.

Authors:  Robin DiFrancesco; Getrude Maduke; Rutva Patel; Charlene R Taylor; Gene D Morse
Journal:  Bioanalysis       Date:  2013-02       Impact factor: 2.681

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.